

as
alkyl moiety, or tetrazolyl optionally protected with an optionally substituted lower (C₁₋₄) alkyl or acyl group; R^{2c} is tetrazolyl optionally protected with an optionally substituted lower (C₁₋₄) alkyl or acyl group, or carboxyl optionally protected with an optionally substituted lower (C₁₋₄) alkyl group; R" is hydrogen, halogen, lower (C₁₋₄) alkyl, lower (C₁₋₄) alkoxy, nitro or -CO-D"^c wherein D"^c is hydroxyl or lower (C₁₋₂) alkoxy optionally substituted with hydroxyl, lower (C₁₋₄) alkoxy, lower (C₂₋₆) alkanoyloxy or 1-lower (C₁₋₆) alkoxycarbonyloxy on the alkyl moiety, or amino optionally substituted with lower (C₁₋₄) alkyl; Y is -O-, -S-, or -N(R^{4c})- wherein R^{4c} is hydrogen or a lower (C₁₋₄) alkyl group; or a pharmaceutically acceptable salt thereof. --

REMARKS


The present claims are claims 1-28 and 30-88.

The specification and claims have been amended to correct various minor clerical errors. Additionally, formulae I' and I" have been revised in order to distinguish the variables included therein.

An early and favorable action on the merits is respectfully requested.

WEGNER, CANTOR, MUELLER & PLAYER
P.O. Box 18218
Washington, D.C. 20036-8218
(202) 887-0400
Atty. Docket P4414-22823
Date: August 14, 1991
HIC:JET:jol/leg

Respectfully submitted,


Herbert I. Cantor
Reg. No. 24,392